1. The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries
- Author
-
Bahl, R, Gulmezoglu, AM, My, HN, Oladapo, OT, Piaggio, G, Vogel, JP, Baqui, AH, Chowdhury, SB, Shahidullah, M, Goudar, S, Dhaded, SM, Mallapur, AA, Bidri, S, Misra, S, Kinuthia, J, Qureshi, Z, Were, F, Ayede, AI, Fawole, B, Adesina, OA, Adejuyigbe, EA, Kuti, O, Ariff, S, Sheikh, L, Soofi, S, Neilson, J, Althabe, F, Chellani, H, Molyneux, E, Mugerwa, K, Yunis, K, Campodonico, L, Carroli, G, Gamerro, H, Giordano, D, Patterson, J, Khanam, R, Harrison, M, Mannan, MA, Nasrin, B, Ahmed, S, Begum, N, Sultana, S, Khatoon, S, Ara, A, Chowdhury, MA, Dey, PR, Bhowmik, DK, Sabur, MA, Azad, MT, Ara, G, Akter, S, Bari, S, Rahman, MM, Yasmin, F, Matin, MA, Choudhury, SF, Goudar, SS, Metgud, MC, Pujar, YV, Somannavar, MS, Vernekar, SS, Herekar, V, Machakanur, VL, Andola, SS, Katageri, GM, Math, S, Yelamali, BC, Pol, R, Ramdurg, U, Bidri, SR, Mathpati, S, Patil, P, Lakhkar, BB, Patil, MM, Gudadinni, MR, Misra, SS, Padhi, M, Das, LB, Das, L, Nanda, SS, Pradhan, MJ, Mohanty, GSG, Nayak, RS, Singh, BS, Osoti, A, Gwako, G, Laving, A, Mohamed, H, Nassir, F, Mohamed, N, Barassa, A, Ogindo, J, Gwer, B, Salome, W, Ochieng, G, Githua, NJ, Lusweti, B, Okunlola, MA, Falade, AG, Ashubu, OF, Busari, O, Sanni, W, Ebedi, A, Kate, EI, Violet, O, Idris, HA, Sallau, FA, Viola, OC, Osaretin, EL, Irinyenikan, TA, Olubosede, OA, Omololu, OM, Runsewe, O, Imam, Z, Akintan, AL, Owa, OO, Oluwafemi, OR, Eniowo, IP, Fabamwo, A, Disu, E, Awowole, IO, Adeyemi, AB, Fehintola, AO, Anyabolu, HC, Kuti, BP, Famurewa, OC, Ande, ABA, Okonkwo, I, Peter, AA, Olugbenga, M, Adesiyun, O, Isah, AD, Kudirat, OE, Abiodun, O, Dedeke, OF, Oyeneyin, L, Akinkunmi, FB, Soofi, SB, Najimi, N, Ali, M, Anwar, J, Zulfiqar, S, Sikander, R, Rani, S, Sheikh, S, Memon, S, Bahl, R, Gulmezoglu, AM, My, HN, Oladapo, OT, Piaggio, G, Vogel, JP, Baqui, AH, Chowdhury, SB, Shahidullah, M, Goudar, S, Dhaded, SM, Mallapur, AA, Bidri, S, Misra, S, Kinuthia, J, Qureshi, Z, Were, F, Ayede, AI, Fawole, B, Adesina, OA, Adejuyigbe, EA, Kuti, O, Ariff, S, Sheikh, L, Soofi, S, Neilson, J, Althabe, F, Chellani, H, Molyneux, E, Mugerwa, K, Yunis, K, Campodonico, L, Carroli, G, Gamerro, H, Giordano, D, Patterson, J, Khanam, R, Harrison, M, Mannan, MA, Nasrin, B, Ahmed, S, Begum, N, Sultana, S, Khatoon, S, Ara, A, Chowdhury, MA, Dey, PR, Bhowmik, DK, Sabur, MA, Azad, MT, Ara, G, Akter, S, Bari, S, Rahman, MM, Yasmin, F, Matin, MA, Choudhury, SF, Goudar, SS, Metgud, MC, Pujar, YV, Somannavar, MS, Vernekar, SS, Herekar, V, Machakanur, VL, Andola, SS, Katageri, GM, Math, S, Yelamali, BC, Pol, R, Ramdurg, U, Bidri, SR, Mathpati, S, Patil, P, Lakhkar, BB, Patil, MM, Gudadinni, MR, Misra, SS, Padhi, M, Das, LB, Das, L, Nanda, SS, Pradhan, MJ, Mohanty, GSG, Nayak, RS, Singh, BS, Osoti, A, Gwako, G, Laving, A, Mohamed, H, Nassir, F, Mohamed, N, Barassa, A, Ogindo, J, Gwer, B, Salome, W, Ochieng, G, Githua, NJ, Lusweti, B, Okunlola, MA, Falade, AG, Ashubu, OF, Busari, O, Sanni, W, Ebedi, A, Kate, EI, Violet, O, Idris, HA, Sallau, FA, Viola, OC, Osaretin, EL, Irinyenikan, TA, Olubosede, OA, Omololu, OM, Runsewe, O, Imam, Z, Akintan, AL, Owa, OO, Oluwafemi, OR, Eniowo, IP, Fabamwo, A, Disu, E, Awowole, IO, Adeyemi, AB, Fehintola, AO, Anyabolu, HC, Kuti, BP, Famurewa, OC, Ande, ABA, Okonkwo, I, Peter, AA, Olugbenga, M, Adesiyun, O, Isah, AD, Kudirat, OE, Abiodun, O, Dedeke, OF, Oyeneyin, L, Akinkunmi, FB, Soofi, SB, Najimi, N, Ali, M, Anwar, J, Zulfiqar, S, Sikander, R, Rani, S, Sheikh, S, and Memon, S
- Abstract
BACKGROUND: Antenatal corticosteroids (ACS) have long been regarded as a cornerstone intervention in mitigating the adverse effects of a preterm birth. However, the safety and efficacy of ACS in hospitals in low-resource countries has not been established in an efficacy trial despite their widespread use. Findings of a large cluster-randomized trial in six low- and middle-income countries showed that efforts to scale up ACS use in low-resource settings can lead to harm. There is equipoise regarding the benefits and harms of ACS use in hospitals in low-resource countries. This randomized controlled trial aims to determine whether ACS are safe and efficacious when given to women at risk of imminent birth in the early preterm period, in hospitals in low-resource countries. METHODS/DESIGN: The trial design is a parallel, two-arm, double-blind, individually randomized, placebo-controlled trial of ACS (dexamethasone) for women at risk of imminent preterm birth. The trial will recruit 6018 women in participating hospitals across five low-resource countries (Bangladesh, India, Kenya, Nigeria and Pakistan). The primary objectives are to compare the efficacy of dexamethasone with placebo on survival of the baby and maternal infectious morbidity. The primary outcomes are: 1) neonatal death (to 28 completed days of life); 2) any baby death (any stillbirth postrandomization or neonatal death); and 3) a composite outcome to assess possible maternal bacterial infections. The trial will recruit eligible, consenting pregnant women from 26 weeks 0 days to 33 weeks 6 days gestation with confirmed live fetuses, in whom birth is planned or expected within 48 h. The intervention comprises a regimen of intramuscular dexamethasone sodium phosphate. The comparison is an identical placebo regimen (normal saline). A total of 6018 women will be recruited to detect a reduction of 15% or more in neonatal deaths in a two-sided 5% significance test with 90% power (including 10% loss to follow-up).
- Published
- 2019